阿利魯單抗

阿利魯單抗
單株抗體
種類	?
目標	整合素α4β7（英語：LPAM-1）
臨床資料
其他名稱	AMG 181
ATC碼	未分配;
識別資訊
CAS號	1342290-43-0
ChemSpider	none;
UNII	Y9UQ37XT2T;
KEGG	D10540;
化學資訊
化學式	C6362H9806N1686O2014S52
摩爾質量	143,803.34 g·mol−1

阿利魯單抗（INN：abrilumab；開發代號：AMG 181）是一種抗α₄β₇（英語：LPAM-1）單株抗體，^[1]設計用於治療炎症性腸病^[1]、潰瘍性結腸炎^[2]和克羅恩病。^[3]

該藥物由安進公司和阿斯利康旗下的MedImmune（英語：MedImmune）開發。^[4]針對該藥物的開發已於2016年停止。^[5]

參考資料

^ ^1.0 ^1.1 Sandborn, William J.; Cyrille, Marcoli; Hansen, Mark Berner; Feagan, Brian G.; Loftus, Edward V.; Rogler, Gerhard; Vermeire, Severine; Cruz, Martha L.; Yang, Jun; Boedigheimer, Michael J.; Abuqayyas, Lubna. Efficacy and Safety of Abrilumab in a Randomized, Placebo-Controlled Trial for Moderate-to-Severe Ulcerative Colitis. Gastroenterology. 2019-03, 156 (4). ISSN 1528-0012. PMID 30472236. doi:10.1053/j.gastro.2018.11.035.
^ Hibi, Toshifumi; Motoya, Satoshi; Ashida, Toshifumi; Sai, Souken; Sameshima, Yukinori; Nakamura, Shiro; Maemoto, Atsuo; Nii, Masahiro; Sullivan, Barbara A.; Gasser, Robert A.; Suzuki, Yasuo. Efficacy and safety of abrilumab, an α4β7 integrin inhibitor, in Japanese patients with moderate-to-severe ulcerative colitis: a phase II study. Intestinal Research. 2019-07, 17 (3) [2024-05-25]. ISSN 1598-9100. PMC 6667363  . PMID 30739435. doi:10.5217/ir.2018.00141. （原始內容存檔於2024-05-25）.
^ Pan, Wei-Jian; Köck, Kathleen; Rees, William A; Sullivan, Barbara A; Evangelista, Christine M; Yen, Mark; Andrews, Jane M; Radford-Smith, Graham L; Prince, Peter J; Reynhardt, Kaz O; Doherty, David R. Clinical pharmacology of AMG 181, a gut-specific human anti-α4β7 monoclonal antibody, for treating inflammatory bowel diseases. British Journal of Clinical Pharmacology. 2014-12, 78 (6) [2024-05-25]. ISSN 0306-5251. PMC 4256621  . PMID 24803302. doi:10.1111/bcp.12418. （原始內容存檔於2024-09-25）.
^ Abrilumab - Amgen/AstraZeneca - AdisInsight. adisinsight.springer.com. [2024-05-25]. （原始內容存檔於2017-11-01）.
^ abrilumab | Ligand page | IUPHAR/BPS Guide to PHARMACOLOGY. www.guidetopharmacology.org. [2024-05-25]. （原始內容存檔於2024-11-30）.

[pmid30472236-1] 1.0 ^1.1 Sandborn, William J.; Cyrille, Marcoli; Hansen, Mark Berner; Feagan, Brian G.; Loftus, Edward V.; Rogler, Gerhard; Vermeire, Severine; Cruz, Martha L.; Yang, Jun; Boedigheimer, Michael J.; Abuqayyas, Lubna. Efficacy and Safety of Abrilumab in a Randomized, Placebo-Controlled Trial for Moderate-to-Severe Ulcerative Colitis. Gastroenterology. 2019-03, 156 (4). ISSN 1528-0012. PMID 30472236. doi:10.1053/j.gastro.2018.11.035.

[pmid30739435-2] Hibi, Toshifumi; Motoya, Satoshi; Ashida, Toshifumi; Sai, Souken; Sameshima, Yukinori; Nakamura, Shiro; Maemoto, Atsuo; Nii, Masahiro; Sullivan, Barbara A.; Gasser, Robert A.; Suzuki, Yasuo. Efficacy and safety of abrilumab, an α4β7 integrin inhibitor, in Japanese patients with moderate-to-severe ulcerative colitis: a phase II study. Intestinal Research. 2019-07, 17 (3) [2024-05-25]. ISSN 1598-9100. PMC 6667363  . PMID 30739435. doi:10.5217/ir.2018.00141. （原始內容存檔於2024-05-25）.

[pmid24803302-3] Pan, Wei-Jian; Köck, Kathleen; Rees, William A; Sullivan, Barbara A; Evangelista, Christine M; Yen, Mark; Andrews, Jane M; Radford-Smith, Graham L; Prince, Peter J; Reynhardt, Kaz O; Doherty, David R. Clinical pharmacology of AMG 181, a gut-specific human anti-α4β7 monoclonal antibody, for treating inflammatory bowel diseases. British Journal of Clinical Pharmacology. 2014-12, 78 (6) [2024-05-25]. ISSN 0306-5251. PMC 4256621  . PMID 24803302. doi:10.1111/bcp.12418. （原始內容存檔於2024-09-25）.

[4] Abrilumab - Amgen/AstraZeneca - AdisInsight. adisinsight.springer.com. [2024-05-25]. （原始內容存檔於2017-11-01）.

[5] rilumab | Ligand page | IUPHAR/BPS Guide to PHARMACOLOGY. www.guidetopharmacology.org. [2024-05-25]. （原始內容存檔於2024-11-30）.

[1]

[2]

[3]

[4]

[5]

單株抗體
種類	?
目標	整合素α₄β₇（英語：LPAM-1）
臨床資料
其他名稱	AMG 181
ATC碼	未分配
識別資訊
CAS號	1342290-43-0
ChemSpider	none
UNII	Y9UQ37XT2T
KEGG	D10540
化學資訊
化學式	C₆₃₆₂H₉₈₀₆N₁₆₈₆O₂₀₁₄S₅₂
摩爾質量	143,803.34 g·mol⁻¹